BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company’s protein sequencing instrument, Platinum® available for the first time in Japan..

康涅狄格州布兰福德（BUSINESS WIRE）--Quantum Si Incorporated（纳斯达克：QSI）（“Quantum Si”，“QSI”或“公司”），蛋白质测序公司™, 今天宣布，它已与一家新的分销商达成协议，该分销商将在日本首次提供该公司的蛋白质测序仪器Platinum®。。

TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si’s next-generation protein sequencer™ and associated consumables throughout Japan. “Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences.

TOMY Digital Biology Co.，Ltd.是一家著名的进口商和分销商，其历史可以追溯到20世纪50年代，它将经销Quantum Si的下一代蛋白质测序仪™ 以及日本各地的相关消耗品。“与Quantum Si合作标志着TOMY数字生物学的关键时刻，符合我们推进生命科学的承诺。

We’re poised to empower Japanese researchers with cutting edge technology, fostering unparalleled discoveries,” said Kenjiro Tominaga, Owner, President and CEO of TOMY Digital Biology..

TOMY Digital Biology的所有者、总裁兼首席执行官丰田健二郎（KenjiroTominaga）表示：“我们准备为日本研究人员提供尖端技术，促进无与伦比的发现。”。。

TOMY Digital Biology’s commitment to delivering cutting-edge solutions and its alignment with Quantum-Si's vision for scientific innovation make this a significant step forward in providing researchers in Japan access to state-of-the-art technology for next-generation protein sequencing™.

TOMY Digital Biology致力于提供尖端解决方案，并与Quantum Si的科学创新愿景保持一致，这在为日本研究人员提供下一代蛋白质测序的最新技术方面迈出了重要的一步™.

Jeff Hawkins, CEO of Quantum-Si, expressed his enthusiasm about this move, stating: 'We are thrilled to work with TOMY Digital Biology to introduce Platinum, our revolutionary protein sequencing instrument, to the vibrant scientific community in Japan. We believe that through TOMY's exceptional distribution capabilities and our groundbreaking technology, we will empower researchers in Japan to achieve new milestones in their scientific endeavors.'.

Quantum Si首席执行官杰夫·霍金斯（Jeff Hawkins）对这一举措表示了热情，他表示：“我们很高兴与TOMY数字生物学合作，将我们革命性的蛋白质测序仪器铂引入日本充满活力的科学界。我们相信，通过TOMY出色的分销能力和开创性的技术，我们将使日本的研究人员能够在他们的科学努力中取得新的里程碑。”。

About Quantum-Si Incorporated

关于Quantum Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

蛋白质测序公司Quantum Si™, 专注于彻底改变蛋白质组学不断发展的领域。该公司的一套技术由同类半导体芯片提供动力，该芯片旨在实现下一代单分子蛋白质测序和蛋白质组学研究数字化，以推动药物发现和诊断超越DNA测序的可能性。

Learn more at www.quantum-si.com.

有关更多信息，请访问www.quantum-si.com。

About TOMY Digital Biology Co., Ltd.

关于TOMY数字生物有限公司。

TOMY Digital Biology Co., Ltd. spun off from TOMY Seiko, a manufacturer of scientific research instruments in 2001. TOMY Digital Biology has two functions, import and export. One department imports unique life science research products from other countries and distributes them to the Japan market. The other department exports TOMY products to other countries.

TOMY数字生物学有限公司于2001年从科学研究仪器制造商TOMY Seiko分拆出来。TOMY数字生物学有两个功能，导入和导出。一个部门从其他国家进口独特的生命科学研究产品，并将其分销到日本市场。另一个部门向其他国家出口TOMY产品。

Learn more at www.digital-biology.co.jp.

更多信息，请访问www.digital-biology.co.jp。

Forward Looking Statements

前瞻性声明

This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events.

本新闻稿包括1995年《美国私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性声明”。公司的实际结果可能与其预期、估计和预测不同，因此，您不应将这些前瞻性陈述视为对未来事件的预测。

Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements.

诸如“期望”、“估计”、“项目”、“预算”、“预测”、“预期”、“打算”、“计划”、“可能”、“意志”、“可能”、“应该”、“相信”、“预测”、“潜力”、“继续”等词语以及类似的表达（或此类词语或表达的负面版本）旨在识别此类前瞻性陈述。

These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements.

这些前瞻性陈述包括但不限于公司对未来业绩以及产品和服务的开发和商业化的期望。这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异。

Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of.

这些因素大多不在公司的控制范围内，很难预测。可能导致这种差异的因素包括但不限于：新型冠状病毒对公司业务的影响；无法维持公司A类普通股在纳斯达克股票市场的上市；确认企业合并预期收益的能力，这可能会受到竞争以及公司盈利增长和管理增长以及留住关键员工的能力等因素的影响；我们正在进行的领导层过渡；适用法律法规的变更；公司未来融资的能力；的成功、成本和时机。